The ROE as of November 2024 (TTM) for Aceragen, Inc. (ACGN) is -46.48%

According to Aceragen, Inc.’s latest financial reports and current stock price. The company's current ROE is -46.48%. This represents a change of 174.57% compared to the average of -16.93% of the last 4 quarters.

Aceragen, Inc. (ACGN) Historical ROE (quarterly & annually)

How has ACGN ROE performed in the past?

The mean historical ROE of Aceragen, Inc. over the last ten years is 50.74%. The current -46.48% ROE has changed -191.61% with respect to the historical average. Over the past ten years (40 quarters), ACGN's ROE was at its highest in in the March 2021 quarter at 273.59%. The ROE was at its lowest in in the March 2020 quarter at -6122.92%.

Aceragen, Inc. (ACGN) ROE by Quarter and Year

Discovering the peaks and valleys of Aceragen, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Aceragen, Inc. (ACGN) Average ROE

How has ACGN ROE performed in the past?

The current ROE of Aceragen, Inc. (ACGN) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Aceragen, Inc. (ACGN) ROE vs. Peers

How is ACGN’s ROE compared to its peers?

Aceragen, Inc.’s ROE is less than Addex Therapeutics Ltd (105.53%), less than ERYTECH Pharma S.A. (6.80%), greater than Soligenix, Inc. (-256.63%), greater than Avenue Therapeutics, Inc. (-749.10%), less than Akari Therapeutics, Plc (1.04%), less than Armata Pharmaceuticals, Inc. (182.35%), greater than Anebulo Pharmaceuticals, Inc. (-138.92%), less than Scopus BioPharma Inc. (911.69%), greater than Processa Pharmaceuticals, Inc. (-195.22%), greater than Neoleukin Therapeutics, Inc. (-47.64%), greater than Senti Biosciences, Inc. (-91.09%), greater than Hillstream BioPharma, Inc. (-47249.59%), greater than SAB Biotherapeutics, Inc. (-94.04%), greater than Quoin Pharmaceuticals, Ltd. (-112.11%), greater than Cocrystal Pharma, Inc. (-73.89%), greater than iBio, Inc. (-145.25%), greater than Bio-Path Holdings, Inc. (-2842.40%), greater than Tempest Therapeutics, Inc. (-201.10%), greater than RenovoRx, Inc. (-403.38%), greater than Acrivon Therapeutics, Inc. Common Stock (-47.31%), greater than Acurx Pharmaceuticals, Inc. (-371.20%),

Build a custom stock screener for Aceragen, Inc. (ACGN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aceragen, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Aceragen, Inc. (ACGN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Aceragen, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.